Sanofi and Regeneron Hit Asthma Phase III Endpoints With Dupixent

Dupixent has upped the ante on Nucala and Cinqair, showing broad activity in Phase III in asthma. But will it be bested by AstraZeneca and Amgen's tezepelumab?

Peacock — Sanofi and Regeneron's Expanding Pipeline Pride • Source: Shutterstock

Sanofi and Regeneron Pharmaceuticals Inc.'s novel therapy Dupixent (dupilumab) has hit both primary endpoints in a Phase III trial in asthma, showing a greater benefit in those most allergic form of the disease and setting the stage for a US FDA filing to expand its indications by the end of the year.

The product – which was approved in March by the FDA for the treatment of moderate-to-severe atopic dermatitis in adult...